



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: December 19, 2008

To: NCCTG Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0177, A Phase I/II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Per Addendum 14, “Inflammation of the lungs” was to be reflected under the “Rare but serious” sections for OSI-774 in the IB and IC consent forms but was inadvertently omitted. This has now been corrected in the protocol and the separate consent form documents. Please download these corrected versions from the NCCTG web site.

If you have any questions concerning this communication, please contact me at 507/284-4852.

Thank you.

JW/dg